Microarray screening for target genes of the proto-oncogene PLAG1. by Voz, Marianne et al.
Published in : Oncogene (2004), vol. 23, pp. 179-191. 
Status : Postprint (Author’s version) 
 
Microarray screening for target genes of the proto-oncogene PLAG1 
 
Marianne L Voz1,2, Janick Mathys3, Karen Hensen1, Hélène Pendeville2, Isabelle Van Valckenborgh1, Christophe 
Van Huffel4, Marcela Chavez1, Boudewijn Van Damme5, Bart De Moor3, Yves Moreau2 and Wim JM Van de 
Ven1 
1 Laboratory for Molecular Oncology, Center for Human Genetics, KU Leuυen & Flanders Interuniυersity Institute for Biotechnology, 
Herestraat 49, Leuυen B-3000, Belgium; 2Laboratoire de Biologie Moléculaire et de Génie Génétique, Université de Liège, Allée du XVI-
août, Institut de Chimie, B6, Sart-Tilman B-4000, Belgium; 3ESAT-SCD, KU Leuυen, Kasteelpark Arenberg 10, Leuυen B-3001, Belgium; 4 
Department of Genomics, Starlab NV/SA, Emgeland, 555 B-1180 Busselles, Belgium; 5 Department of Morphology and Molecular 
Pathology, Katholieke Uniυersiteit Leuυen, Minderbroederstraat 33, Leuυen B-3000, Belgium 
Abstract 
PLAG1 is a proto-oncogene whose ectopic expression can trigger the development of pleomorphic adenomas of 
the salivary glands and of lipoblastomas. As PLAG1 is a transcription factor, able to activate transcription 
through the binding to the consensus sequence GRGGC(N)6-8GGG, its ectopic expression presumably results in 
the deregulation of target genes, leading to uncontrolled cell proliferation. The identification of PLAG1 target 
genes is therefore a crucial step in understanding the molecular mechanisms involved in PLAG1-induced 
tumorigenesis. To this end, we analysed the changes in gene expression caused by the conditional induction of 
PLAG1 expression in fetal kidney 293 cell lines. Using oligonucleotide microarray analyses of about 12000 
genes, we consistently identified 47 genes induced and 12 genes repressed by PLAG1. One of the largest classes 
identified as upregulated PLAG1 targets consists of growth factors such as the insulin-like growth factor II and 
the cytokine-like factor 1. The in silico search for PLAG1 consensus sequences in the promoter of the 
upregulated genes reveals that a large proportion of them harbor several copies of the PLAG1-binding motif, 
suggesting that they represent direct PLAG1 targets. Our approach was complemented by the comparison of the 
expression profiles of pleomorphic adenomas induced by PLAG1 versus normal salivary glands. Concordance 
between these two sets of experiments pinpointed 12 genes that were significantly and consistently upregulated 
in pleomorphic adenomas and in PLAG1-expressing cells, identifying them as putative PLAG1 targets in these 
tumors. 
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Introduction 
Oncogenic activation of the PLAG1 gene on 8q12 is a crucial event in the formation of pleomorphic adenomas of 
the salivary glands. This activation mainly results from recurrent chromosomal translocations that lead to 
promoter substitution between PLAG1, a gene primarily expressed in fetal tissues, and more broadly expressed 
genes (Kas et al., 1997; Voz et al., 1998; Astrom et al., 1999). The three translocation partners characterized so 
far are the β-catenin gene (Kas et al., 1997), the leukemia inhibitory factor receptor gene (Voz et al., 1998) and 
the elongation factor SII gene (Astrom et al., 1999). Breakpoints invariably occur in the 5' noncoding region of 
the PLAG1 gene, leading to an exchange of the regulatory control elements while preserving the PLAG1 coding 
sequence. The replacement of the PLAG1 promoter, inactive in adult salivary glands, by a strong promoter 
derived from the translocation partner, leads to ectopic expression of PLAG1 in the tumor cells. This abnormal 
PLAG1 expression presumably results in a deregulation of PLAG1 target genes, causing salivary gland 
tumorigenesis. 
PLAG1 promoter swapping is also a central oncogenic event in lipoblastomas (Hibbard et al., 2000). Similarly, 
the entire PLAG1 coding sequence is placed under the control of an active and ectopic promoter region. The 
fusion partners discovered to date are the hyaluronic acid synthase 2 and the collagen 1α2 genes. These genes 
were never reported as translocation partners in pleomorphic adenomas, suggesting specific fusion partners for 
lipoblastomas. 
Ectopic PLAG1 expression is not only the result of PLAG1 promoter substitution. PLAG1 overexpression has 
also been found in tumors without 8q12 translocations, such as pleomorphic adenomas of the salivary glands 
with 12q15 translocations or normal karyotype, in uterine leiomyomas, leiomyosarcomas and in smooth muscle 
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tumors (Astrom et al., 1999). This emphasizes the importance of PLAG1 overexpression in tumorigenesis. 
Recently, we proved that PLAG1 acts as a proto-oncogene with mitogenic and transforming potential (Hensen et 
al., 2002). Indeed, NIH3T3 cell lines engineered to overexpress PLAG1 were able to proliferate in medium 
containing 1% serum, suggesting that PLAG1 at least partially abrogates the serum requirement for the growth 
of NIH3T3 cells. Moreover, these cells displayed the typical features of neoplastic transformation: the cells lost 
cell-cell contact inhibition, showed anchorage-independent growth and were able to form tumors in nude mice. 
PLAG1 is a transcription factor that contains seven canonical C2H2 zinc-fingers and a serine-rich C-terminus that 
exhibits transactivation capacities when fused to the Gal4 DNA-binding domain (Kas et al., 1998). PLAG1 binds 
a bipartite DNA element containing a core sequence, GRGGC, and a G-cluster, GGG, separated by six to eight 
random nucleotides (Voz et al., 2000). Potential PLAG1-binding sites were found in several genes and notably 
in promoter 3 of the human insulinlike growth factor II (IGF-II) gene. We have shown that PLAG1 is actually 
able to bind to the IGF-II promoter 3 and can stimulate its activity (Voz et al., 2000). Moreover, induction of 
PLAG1 expression in the fetal kidney cell line 293 leads to a drastic stimulation of the IGF-II transcript deriving 
from the P3 promoter. Finally, this IGF-II transcript is highly expressed in salivary gland adenomas 
overexpressing PLAG1, while it is not detectable in adenomas without upregulated PLAG1 expression or in 
normal salivary gland (nsg) tissues. All these results indicate that IGF-II is a bona fide PLAG1 target gene, 
providing us with the first clue for understanding the role of PLAG1 in salivary gland tumor development. 
To identify other target genes of PLAG1, we screened high-density oligonucleotide microarrays representing 
about 12000 human genes for transcripts whose levels were modified in pleomorphic adenomas with PLAG1 
ectopic expression compared to normal salivary glands. We also monitored gene expression profiles shortly after 
inducing PLAG1 expression in genetically engineered human epithelial kidney 293 cell lines. Such cell lines 
were generated by isolating independent clones that had stably integrated a DNA fragment enabling zinc-
inducible expression of PLAG1 or β-galactosidase (β-gal) used as control. Comparative evaluation of all these 
results allowed us to identify potential PLAG1 targets in pleomorphic adenomas. Finally, we looked for PLAG1-
binding motifs in the promoter region of the identified genes to get an additional indication of whether they are 
direct targets of PLAG1. 
Material and methods 
Tumor samples and cell lines 
Specimens of primary pleomorphic adenomas of the salivary glands were obtained from patients at the time of 
surgery. Chromosome metaphases of tumor cells were prepared from short-term primary cultures according to a 
routine method, and the karyotype of the tumors was determined. Tumor G27 carries a t(3;8)(p21;q12) as sole 
abnormality. Tumor G18 carries a t(6;8)(p21;q12), and tumor G19 carries a t(4;8)(p21;q12) among other 
abnormalities. Tumors F32, F36 and G30 present a normal diploid karyotype, while tumor F35 carries multiple 
chromosomal abnormalities. The karyotype of tumors K5773, K3149 and K3259 was not available. Normal 
salivary gland specimens H1, H2, H3 and G12 are biopsies corresponding to the normal salivary gland 
counterpart from patients presenting a pleomorphic adenoma. 
The inducible PLAG1 (P1-8 and P1-32 clones) and β-gal (B-1 and B-57 clones)-expressing cell lines were 
obtained by stable integration of the expression vector pSAR-MT-FLAG-PLAG1 or pSAR-MT-β-gal (Morin et 
al., 1996) in the human fetal kidney epithelial cell line 293 (ATCC, CRL 1573) (Hensen et al., 2002). Individual 
colonies were selected on the basis of high zinc-inducible expression of PLAG1 or β-gal, as estimated by 
Western blot analysis. For expression profile analysis, cells were grown at midconfluency and either treated with 
100 µM ZnCl2 for 16 h or left untreated. 
Preparation of RNA and Northern blot analysis 
Total RNA was extracted from primary tumors and normal salivary gland biopsies using the guanidine 
thiocyanate method, and further purified using Rneasy spin columns (Qiagen, Valencia, CA, USA), according to 
the manufacturer's protocol. The total RNA from the cell lines was directly isolated using Rneasy columns. 
Northern blot analysis was performed according to standard procedures. For filter hybridizations, probes were 
radiolabeled with α-32P-dCTP using the megaprime DNA-labeling system (Amersham). A 1.5 kb cDNA probe 
containing the complete PLAG1 ORF was used for the detection of the PLAG1 transcripts. The human IGF-II 
exon 9 probe, common to the four different transcripts P1, P2, P3 and P4, was generated by PCR and contained 
nucleotides 7970-8774 of the published gene sequence (Dull et al., 1984) (GenBank/EMBL, accession number 
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X03562). As for the cellular retinoic acid-binding protein II (CRABP-II), the complete cDNA (M68867) 
obtained from RZPD (Germany) was used as probe. Finally, PCR amplicons corresponding to cytokine-like 
factor 1 (CLF-1) (1247-1614 bp of the sequence AF059293 (GenBank/EMBL)), CRP2 (305-981 bp of D42123), 
PIGF (398-1396 bp of X54936) and p57kip2 (1048-1316 bp of U22398) were used as probes. 
Microarray analysis 
Preparation of cRNA and subsequent steps leading to hybridization, scanning and data analysis were performed 
according to Affymetrix guidelines (Affymetrix, Santa Clara, CA, USA) (Lipshutz et al., 1999). Briefly, 20 µg 
of total RNA were converted into double-stranded cDNA using a oligo(dT) primer containing the T7 promoter. 
This double-stranded cDNA was then used in an in vitro cRNA synthesis reaction using T7 RNA polymerase 
and biotinylated cRNA ribonucleotides from a bioarray high-yield RNA transcript labeling kit (Enzo 
Diagnostics, Farmingdale, NY, USA). Biotin-labeled cRNA was purified with a RNeasy column (Qiagen) and 
quantified by spectrophotometry. Fragmentation of cRNA was performed at 95°C for 35 min. The quality of the 
procedure was evaluated by hybridizing 5 µg of cRNA to a Test3 microarray (Affymetrix). A quantity of 15 µg 
of the remaining fragmented cRNA was subsequently hybridized to HuGeneFL Array (Affymetrix) for 16 h at 
45°C. After washing and staining, the arrays were scanned in an HP/Affymetrix scanner at 570 nm. The scanned 
images were analysed using Affymetrix Microarray Suite 4.2 software. The image for each GeneChip was scaled 
such that the average intensity value for all arrays was adjusted to a target intensity of 700; this value 
corresponds to the average intensity obtained for all the arrays analysed in this study. Scaled average differences 
values (SADVs) lower than 50 were arbitrarily set to a baseline value of 50 to avoid unrealistic level of 
stimulation. Therefore, for the probe sets where the values in the reference samples are at the background level, 
the rates of stimulation or repression could not be accurately calculated and are probably underestimated. In this 
situation, the fold stimulation obtained is preceded by the sign ' ≥ ' and the fold repression by the sign ' ≤ '. 
Computational search for PLAG1 motifs 
Search for the PLAG1-binding consensus sequence GRGGC(N)6-8GGG was performed using regular 
expressions. The search was done on both strands, without allowing any overlap of the motifs. For each gene 
whose promoter is not yet defined, we attempted to obtain it by retrieving from the databanks all the cDNAs 
(including ESTs) available for this gene. After alignment, we selected the one that starts at the most upstream 
part of the gene. Finally, we retrieved the sequence located directly upstream of this selected cDNA from the 
human genome database and considered this sequence as the putative promoter region. The random set of 50 
known promoter sequences was obtained by retrieving randomly promoter sequences from the EPD database 
(Praz et al., 2002). The χ2 test, performed to compare the distribution of the PLAG1 motifs in the promoter of the 
target genes versus the random genes population (see Figure 3), has been performed as described on 
http://www.georgetown.edu/faculty/ballc/ webtools/web_chi.html, with four degrees of freedom (genes with four 
or more motifs are grouped together because the numbers become too small and adjustments for continuity 
should be made). 
Results 
Expression profiles of pleomorphic adenomas compared to normal salivary glands 
To decipher the molecular processes involved in PLAG1-induced oncogenesis, we compared the gene expression 
profiles obtained from pleomorphic adenomas displaying PLAG1 ectopic expression to those from normal 
salivary gland specimens. We hybridized oligonucleotide microarrays representing about 12000 genes 
(HuGeneFL Array, Affymetrix) with biotinylated cRNA obtained from four different RNA samples, two from 
normal salivary glands (H1 and G12) and two from pleomorphic adenomas (G27 and G19). These tumors carry 
either a t(3;8)(p21;q12) or a t(4;8)(q35;q12) translocation that leads to ectopic activation of PLAG1 expression, 
as judged by Northern blot analysis (data not shown). This activation results from promoter swapping between 
PLAG1 and β-catenin in the t(3;8) and a not yet identified translocation partner in the t(4;8). Comparison of the 
four samples uncovered 627 genes significantly differentially expressed. In all, 373 genes are upregulated at least 
three times in both tumors, while 254 genes are downregulated. Based on SWISSPROT keywords, the 627 
differentially expressed genes have been classified in 14 functional categories. Nine categories are shown in 
Table 1, while the other five categories (signaling proteins, metabolism-related proteins, proteins of the 
extracellular matrix, miscellaneous proteins and proteins of unknown function) are provided online as 
Supplementary Tables 1a and b. The complete data set, including the values of the microarray experiments for 
all the four samples, is also provided online as Supplementary Tables 1c and d. The identity of these genes 
reveals that many aspects of cell physiology are altered in the tumors, as suggested by the change in expression 
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of growth factors, transcription factors, genes regulating apoptosis, cell cycle genes and signaling proteins. It is 
interesting to note that growth factors, growth factors receptors and growth factor-binding proteins are mainly 
found upregulated. Given the cellular diversity found in pleomorphic adenomas, where many different cell types 
including mesenchymal cells can be present, a battery of genes coding for proteins of the extracellular matrix and 
of the cytoskeleton were found to be differentially expressed (e.g. keratin, collagen, fibronectin, tenascin and 
elastin). As expected, PLAG1 transcript is only detected in pleomorphic adenomas while, in normal salivary 
glands, PLAG1 expression levels do not exceed the background, arbitrarily set to a value of 50 (see Material and 
methods for the analysis of the microarray data). Therefore, the level of PLAG1 induction in pleomorphic 
adenoma could not be accurately calculated and was thus estimated to be at least 14-fold (represented in the table 
by the sign ' ≥ '). A drastic upregulation of IGF-II is observed for all the three independent probe sets (the 
stimulations were 76-, ≥ 15-, ≥ 5-fold). Moreover, genes already identified as upregulated in pleomorphic 
adenomas such as the apoptosis regulator Bcl2 (Sunardhi-Widyaputra and Van Damme, 1995; Debiec-Rychter et 
al., 2001), the bone morphogenetic protein 2 (BPM2) (Kusafuka et al., 1998), tenascin (Sunardhi-Widyaputra 
and Van Damme, 1993; Shrestha et al., 1994) and elastin (Grosso, 1996) were stimulated 8.0-, ≥ 8.5- and ≥ 9.3-, 
≥ 9.8-, ≥ 14.7-fold, respectively, which is indicative of the validity of the microarray approach. 
 
Table 1    Expression profiles of pleomorphic adenomas compared to normal salivary glands 
Upregulated     Downregulated 
Growth factors     
76, ≥ 15, ≥ 5 J03242 Insulin-like growth factor IP 0.21 U50330 Bone morphogenetic protein 1 
≥ 10 AF059293 Cytokine-like factor 1 ≤ 0.13 L09753 Tumor necrosis factor ligand 
superfamily member 8 
7.1 M37435 Macrophage colony-stimulating 
factor 1 
   
10.9 M60314 Bone morphogenetic protein 5    
≥ 8.5, ≥ 9.3 M22489 Bone morphogenetic protein 22    
7.4 L42379 Bone-derived growth factor    
≥ 5.8 Hs.112432 Muellerian-inhibiting factor    
4.5 U78110 Neurturin    
3.6 M31682 Inhibin beta B chain    
4.2 U43030 Cardiotrophin-1    
Growth factor receptors     
20.8 M64347 Fibroblast growth factor receptor 3 ≤ 0.16 M59941 Cytokine receptor common beta 
chain 
4.6, 4.7, 4.9 M34641 Basic fibroblast growth factor 
receptor 13 
   
7.9 X75958 BDNF/NT-3 growth factor receptor    
Growth factor-binding proteins    
13.2 M34057 Latent transforming growth factor 
beta-binding protein 1 
   
6.4 Z37976 Latent transforming growth factor 
beta-binding protein 2 
   
6.4, 5.0 M62403 Insulin-like growth factor-binding 
protein 42 
   
Growth regulation proteins     
28.8 0.22 Neuromodulin 0.22 AF078077 Growth arrest and DNA-damage-
inducible protein GADD45 beta 
5.1 U35139 Necdin    
13.6, 6.4 L13698 Growth-arrest-specific protein 12    
4.0 L13720 Growth-arrest-specific protein    
Cell division and cell-cycle-related proteins    
5.5 S78187 M-phase inducer phosphatase 2 ≤ 0.08 Z36714 G2/mitotic-specific cyclin F 
7.1 M92287 G1/S-specific cyclin D3 ≤ 0.2 M81933 M-phase inducer phosphatase 1 
6.7 U73379 Ubiquitin-conjugating enzyme E2 C 0.17 AF004709 Mitogen-activated protein kinase 
13 
≥ 5.4 AF035811 Septin 4    
≥ 5.2 U29725 Mitogen-activated protein kinase 7    
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4.5, 3.8 X57348 14-3-3 protein sigma    
Apoptosis-related proteins     
≥ 7.2 X98172 Caspase-8 0.2 AB007619 Receptor-binding cancer antigen 
(RCAS1) 
≥ 6.2 Y09392 Tumor necrosis factor receptor 
superfamily member 12 
0.15 U19599 BAX protein, cytoplasmic 
isoform delta 
   ≤ 0.10 U64863 Programmed cell death protein 1 
Proto-oncogenes     
≥ 13.9 U65002 Zinc-finger protein PLAG1 0.25 X57110 Signal transduction protein CBL 
≥ 21.6 X12949 Proto-oncogene tyrosine-protein 
kinase receptor ret 
0.23 D78579 Nuclear hormone receptor NOR-1 
≥ 21.3 U16954 Proto-oncogene AF1Q 0.10 M69199 Putative lymphocyte G0/G1 
switch protein 2 
≥ 11.8, 5.9 M14333 Proto-oncogene tyrosine-protein 
kinase FYN2 
   
4.7 D43969 Runt-related transcription factor 1    
4.3 M73554 G1/S-specific cyclin D1    
8.0 M13995 Apoptosis regulator Bcl-2    
4.6 X61118 Rhombotin-2    
Tumor suppressor     
5.6 U81992 Zinc-finger protein PLAGL1    
≥ 7.2 M22898 Cellular tumor antigen p53    
7.1, 3.5, 3.2 D64137 Cyclin-dependent kinase inhibitor 
1C (p57KIP2)3 
   
Transcriptional regulators  Transcription factors 
≥ 23.7, 3.7 M97915 Retinoic acid-binding protein II 
(CRABP-II)2 
0.24, 0.17 Hs. 149923 X box-binding protein-12 
   0.04 X83877 DNA-binding protein ABP/ZF 
≥ 32.9 Hs.99348 Distal-less homeo box 5 (DLX5) 0.07 M97287 DNA-binding protein SATB1 
   0.18 AJ012611 Homeobox protein SIX3 
≥ 11.2 L07919 Distal-less homeo box 2 (DLX2) 0.04 X76732 Nucleobindin 2 [Precursor] 
≥ 6.2 X61755 Homeobox protein Hox-C5 ≤ 0.11 U80987 T-box transcription factor TBX5 
6.2 U66619 SWI/SNF complex 60 kDa subunit 0.14 L19871 Cyclic-AMP-dependent 
transcription factor ATF-3 
7.5, 6.8 X77956 DNA-binding protein inhibitor ID-12 0.22 AB020639 Estrogen-related receptor gamma 
6.2 Hs.34853 DNA-binding protein inhibitor ID-4 0.17 M83667 CCAAT/enhancer binding protein 
delta 
7.1 Hs.76884 DNA-binding protein inhibitor ID-3    
≥ 18.8 AB002305 Aryl hydrocarbon receptor nuclear 
translocator 2 
   
≥ 13.6 AB018303 Smad-and Olf-interacting zinc-finger 
protein 
   
≥ 7.8, 4.7 D13969 DNA-binding protein Mel-182    
3.8 J03258 Vitamin D3 receptor    
5.3 AF041210 Midline 1 protein    
14.5 X96381 Ets-related protein ERM    
4.2 U15655 ETS-domain transcription factor 
ERF 
   
7.6, ≥ 9.6 AF055376 Short-form transcription factor C-
MAF2 
   
11.4 X70683 Transcription factor SOX-4    
≥ 23.5 L31881 Nuclear factor 1 X-type    
13.8 X53390 Nucleolar transcription factor 1    
6.4 AB006909 Microphthalmia-associated 
transcription factor 
   
8.8 AF035528 Mothers against decapentaplegic 
homolog 6 
   
5.3 AF010193 Mothers against decapentaplegic 
homolog 7 
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8.7 X70991 NGFI-A-binding protein 2    
14.7 U49857 Transcriptional activator    
7.7 L07592 Peroxisome proliferator-activated 
receptor delta 
   
Based on SWISSPROT keywords, the 627 genes differentially expressed have been classified into 14 functional categories. Nine categories 
are shown in Table 1, while the other five categories (signaling proteins (e.g. kinases, phosphatases, receptors), metabolism-related proteins 
(e.g. enzymes), proteins of the extracellular matrix (e.g. collagen, fibronectin, tenascin), miscellaneous proteins and proteins of unknown 
function) are provided online as Supplementary Tables 1a and b. The complete data set, including the values of the microarray experiments 
for all the four samples, is also provided online as Supplementary Tables 1c and d. Those genes that were upregulated or downregulated at 
least threefold in both pleomorphic adenoma compared to both controls are considered to be differentially expressed, with the restriction that 
the scaled average difference value (SADV) has to be at least 200 for both tumors in the case of the upregulated genes and for both normal 
salivary specimens in the case of downregulated genes. The values on the left are the ratios (SADV PA1 + SADV PA2/SADV normal 
salivary gland 1 + SADV normal salivary gland 2) obtained for each gene. For genes represented by several probe sets, the value in the 
superscript above its name indicates the number of independent probe sets corresponding to this gene, and the stimulation or repression has 
been calculated independently for each probe set. The ≥ symbol indicates that the SADV values for normal salivary glands are at the 
background level (arbitrarily fixed to 50, see Material and methods), which will lead to an underestimation of the calculated stimulation, and 
the ≤ symbol indicates that the SADV values for the tumor are at the background level, which will lead to an underestimation of the 
repression 
 
Identification of PLAG1 target genes 
In order to identify in this pool of genes differentially expressed in pleomorphic adenomas, those directly under 
the control of PLAG1, expression profiles were monitored shortly after induction of PLAG1 expression in 
genetically engineered human epithelial kidney 293 cell lines. Such cell lines were generated by isolating 
independent clones that had stably integrated a DNA fragment enabling zinc-inducible expression of PLAG1 
(clones P1-8 and P1-32) or of β-gal (clones B-1 and B-57) (Hensen et al., 2002). When these clones are grown in 
the absence of zinc, low exogenous PLAG1 or β-gal expression is detected, while upon induction with 100 µM 
of zinc, the PLAG1 and β-gal transcripts are efficiently synthesized. Induction of PLAG1 expression results in a 
drastic upregulation of IGF-II transcripts that can be already visualized after 5 h of zinc induction, but which 
reaches a maximal level of stimulation at 16 h (data not shown). This delay in obtaining maximal IGF-II 
induction could be due to the fact that the steady state of PLAG1 protein reaches a plateau at 4h and remains 
equal for at least 12 h (data not shown). Therefore, to get maximal induction for the potential PLAG1 targets, 
expression profiles were performed after 16 h of zinc induction. RNA samples were isolated from PLAG1-
expressing clones P1-8 and P1-32 treated with zinc or left untreated, and from the zinc-treated β-gal clones B-1 
and B-57. The comparison between treated versus untreated PLAG1-expressing clones highlighted 85 genes 
induced at least 2.5-fold (Figure 1, red circle). As this pool of genes could comprise genes induced by the zinc 
treatment, we also compared zinc-treated clones expressing PLAG1 versus β-gal clones and identified 111 genes 
stimulated at least threefold (blue circle). This stricter criterion compared to the one applied to the first 
comparison (2.5-fold) was chosen due to the fact that the untreated P1-8 and P1-32 clones expressed already low 
levels of PLAG1, which are likely to reduce the level of stimulation. In total, 47 genes were significantly 
induced in all the four comparative evaluations (Figure 1). As shown in Table 2, a drastic stimulation of the bona 
fide PLAG1 target IGF-II was observed upon PLAG1 induction; the stimulation obtained was of 39- and 32-fold 
when comparing PLAG1 versus β-gal clones, both zinc treated (columns G and L), and of four- and 20-fold for 
the comparison of treated versus untreated PLAG1-expressing clones (columns F and K). The induced genes 
were distributed among nine functional categories including growth factors, transcription factors, proto-
oncogenes, tumor suppressors and signal transduction proteins. Note that PLAG1 transcripts were not found 
upregulated because the probe set used is located in the 3' UTR of the gene, a region that is not present in the 
PLAG1 expression vector. This analysis also reveals a small group of downregulated genes (Table 3). Strikingly, 
all the 12 genes identified were repressed after 16 h of zinc induction (Table 3, columns F, G, K and L) but not at 
9h (column E), suggesting that they are not direct downstream targets of PLAG1. In contrast, most of the 
upregulated genes were already highly induced after 9 h of zinc treatment (31 out of the 47 genes, column E in 
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Figure 1 Venn diagram of the number of genes altered in the three sets of expression profiles. For the upregulated genes, the red circle 
denotes the genes that are induced at least 2.5-fold when comparing treated versus untreated PLAG1-expressing clones (i.e. P1-8 + /P1-8-
≥2.5 and P1-32 + /P1-32-≥2.5). The blue circle represents the genes that are induced at least threefold when comparing treated PLAG1-
expressing clones versus treated β-gal-expressing clones (i.e. P1-8 + /B-1 + ≥3.0 and P1-32 + /B-57 + ≥3.0). The green circle denotes the 
genes which are induced at least threefold when comparing pleomorphic adenoma of the salivary glands versus normal salivary glands (i.e. 
PA G19/nsg H1 ≥3.0 and PA G19/nsg G12≥3.0 and PA G27/nsg H1≥3.0 and PA G27/nsg G12≥3.0) and a SADV for PA G19 and PA 
G27≥200. For the down-regulated genes, the red circle denotes the genes that are repressed at least 2.5-fold when comparing treated versus 
untreated PLAG1-expressing clones (i.e. P1-8 ± ≤0.4 and P1-32 ± ≤0.4). The blue circle represents the genes that are repressed at least 
threefold when comparing treated PLAG1-expressing clones versus treated β-gal-expressing clones (i.e. P1-8 + /B-1 + ≤1/3 and P1-32 + /B-
57 + ≤1/ 3). The green circle denotes the genes which are repressed at least threefold when comparing pleomorphic adenoma of the salivary 
glands versus nsgs (i.e. PA G19/nsg H1≤1/3 and PA G19/nsg G12≤1/3, and PA G27/nsg H1≤1/3 and PA G27/nsg G12≤1/3) and a SADV for 
nsg H1 and nsg G12≥200 
 
 
Table 2    Identification of 47 genes consistently and significantly induced by PLAG1 
AB  C D E F G H IJ  K L M N O 
B1+ P8- P8+ P8+9h P8+9h/P8- P8+/- P8+/B1+ B57+ P32- P32+ P32+/- P32+/B57+ Accession Genes BS 
Growth factors             
144 1462 5604 3505 2.4 3.8 38.9 132 208 4164 20.0 31.6 J03242 Insulin-like growth factor 
II (IGF-II) 
8 
211 169 2319 889 5.3 13.8 11.0 72 107 1249 11.6 17.3 AF059293 Cytokine-like factor- 
1(CLF-1) 
8 
130 108 462 173 1.6 4.3 3.5 234 314 836 2.7 3.6 L42379 Bone-derived growth 
factor (BPGF-1) 
3 
50 50 864 50 1.0 17.3 17.3 50 52 150 2.9 3.0 J00117 Choriogonadotropin beta 
chain (CGB) 
NA 
376 296 1193 976 3.3 4.0 3.2 145 50 461 9.2 3.2 AF024710 Vascular endothelial 
growth factor (VEGF) 
1 
96 120 301 522 4.4 2.5 3.1 50 74 328 4.4 6.6 X54936 Placental growth factor 
(PIGF) 
1 
Transcriptional regulators         
153 1363 9166 2463 1.8 6.7 60.0 53 1240 7512 6.1 141.2 M97815 Retinoic acid-binding 
protein II (CRABP-II) 
1 
82 842 4589 1771 2.1 5.5 55.9 50 517 2485 4.8 49.7 M97815   
50 50 256 50 1.0 5.1 5.1 50 50 150 3.0 3.0 D12765 Adenovirus E1 A 
enhancer binding protein 
(E1 A-1) 
1 
67 225 834 1195 5.3 3.7 12.4 53 59 314 5.3 5.9 U08015 Nuclear factor of 
activated T-cells  
(NF-ATc) 
2 
164 191 1127 210 1.1 5.9 6.9 196 135 628 4.7 3.2 AB021663 Cyclic-AMP-dependent 
transcription factor  
ATF-5 
3 
258 390 994 717 1.8 2.5 3.9 170 417 1048 2.5 6.2 U66619 SWI/SNF complex 60kDa 
submit 
2 
50 50 591 58 1.2 11.8 11.8 50 50 167 3.3 3.3 AF055009 OASIS protein 2 
Oncogene             
52 57 373 103 1.8 6.5 7.2 50 52 195 3.7 3.9 M13995 Apoptosis regulator Bcl-2 5 
Tumor suppressor            
470 138 1303 6281 4.5 9.4 27.7 279 694 2997 4.3 10.8 U22398 Cyclin-dependent kinase 6 
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6 4 inhibitor 1C (p57KIP2) 
95 565 2848 2146 3.8 5.0 30.1 104 113 328 2.9 3.1 U22398   
139 68 837 899 13.2 12.3 6.0 72 121 372 3.1 5.1 D64137   
Proteins involved in signaling         
124 55 1086 294 5.4 19.8 8.8 187 179 648 3.6 3.5 BC027933 Mitogen-activated protein 
kinase11 (MAPK11) 
0 
50 222 910 433 2.0 4.1 18.2 91 50 311 6.2 3.4 U09303 Ephrin-B1 
(EFNB1/EPLG2) 
3 
301 664 2532 1174 1.8 3.8 8.4 240 494 1365 2.8 5.7 AF100153 Connector enhancer of 
KSR-like (CNK1) 
2 
342 630 3041 2235 3.6 4.8 8.9 50 471 1280 2.7 25.6 W27541 Cdc42 effector protein4 
(CEP4) 
3 




112 50 378 193 3.9 7.6 3.4 50 58 164 2.8 3.3 X77533 Activin receptor type IIB 4 








50 169 475 419 2.5 2.8 9.5 50 50 253 5.1 5.1 NM_058178 Neuronal Pentrax in 
Receptor (NPTXR) 
6 
50 50 176 171 3.4 3.5 3.5 50 50 205 4.1 4.1 U19261 TNF receptor associated 
factorl 
1 
70 58 222 122 2.1 3.8 3.2 50 58 181 3.1 3.6 U19261   
50 50 342 61 1.2 6.8 6.8 50 56 352 6.2 7.0 M33552 Lymphocyte-specific 
protein 1 (LSP1) 
2 




Proteins involved in metabolism         
237 300 1953 1765 5.9 6.5 8.2 55 102 382 3.8 6.9 AB003791 Keratan sulfate Gal-6-
sulfotransferase 
1 
50 57 601 528 9.2 10.5 12.0 50 165 611 3.7 12.2 M55153 Transglutaminase 2 
(TGM2) 
NA 
Extra cellular matrix/cytoskeleton proteins      
50 50 343 234 4.7 6.9 6.9 50 55 280 5.1 5.6 L41162 Collagen alpha 3 (IX) 
chain 
3 
50 50 2628 1016 20.3 52.6 52.6 50 50 1089 21.8 21.8 U53204 Plectin 1 3 
50 228 583 612 2.7 2.6 11.7 50 50 410 8.2 8.2 Y00503 Keratin, type 1 
cytoskeletal 19 
3 
77 98 740 55 0.6 7.5 9.6 50 50 157 3.1 3.1 S76756 Microtubule associated 
protein 
0 
50 187 1325 415 2.2 7.1 26.5 57 102 1092 10.7 19.0 M21984 Tropon in T3, fast skeletal 
muscle isoform β 
1 
645 899 4144 3304 3.7 4.6 6.4 594 642 4099 6.4 6.9 AJ012737 Filamin, muscleiso form  2 
Miscellaneous 
80 194 1360 1247 6.4 7.0 16.9 50 50 1386 27.7 27.7 D42123 Cysteine-rich protein 2 
(CRP2/ESP1) 
5 
50 50 705 207 4.1 14.1 14.1 50 50 307 6.1 6.1 U45448 Purino receptor P2X1 2 
50 50 235 240 4.8 4.7 4.7 50 50 191 3.8 3.8 U41518 Aquapo rin-CH IP 0 
357 264 1241 1415 5.4 4.7 3.5 74 50 369 7.4 4.9 U07364 Inward rectifier potassium 
channel 4 
1 
50 50 613 313 6.3 12.3 12.3 68 51 539 10.6 7.9 L37792 Syntaxin 1A 2 
841 604 3743 3717 6.2 6.2 4.4 500 1196 4352 3.6 8.7 AF022813 Tetraspan   (NAG-2) NA 
318 413 1183 540 1.3 2.9 3.7 381 441 1331 3.0 3.5 M20469 Brain-type clathrin light-
chain b 
2 
50 79 931 484 6.1 11.7 18.6 70 98 519 5.3 7.4 M96759 ROD  outer segment 
membrane protein 1 
6 
243 288 1168 586 2.0 4 .1 4.8 185 208 594 2.9 3.2 M87068 Calcium-binding protein 
S100A2 
1 
Unknown              
50 50 363 298 6.0 7.3 7.3 50 56 191 3.4 3.8 AB023171 KIAA09 54 0 
50 50 257 89 1.8 5.1 5.1 50 50 181 3.6 3.6 M60614 Wilms tumor-associated 0 
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protein WIT-1 
91 179 1115 923 5.2 6.2 12.2 94 106 338 3.2 3.6 AI391564 tg16b02.x1 Homo sapiens 
cDNA 
NA 
50 119 543 106 0.9 4.6 10.9 166 58 502 8.7 3.0 AA165701 zo75g08.s1 Homo sapiens 
cDNA 
1 
The 47 genes induced at least threefold when comparing PLAG1 versus β-galactosid ase-expressing clones, both zinc-treated (columns G 
and L) and at least 2.5-fold when comparing treated versus untreated PLAG1-expressing clones (columns F and K) are listed. The columns 
include the following information : the scaled average differences values (SADVs) for the probe sets in the different conditions (columns A-
D, H-J); the accession number of the gene corresponding to the probe set (column M); the number of PLAG1-binding motifs found in the 
first 1000bp of their putative promoter region (column O), numbers in italics meaning that the first 1000bp of the promoter were not 
available in its entirety (only 280 and 158 bp were available for NF-ATc and E1 A-1. respectively), and NA meaning that the promoter was 
not available at all. SADVs of less than 50 were arbitrarily set to a baseline value of 50 to avoid unrealistic levels of stimulation (see Material 
and methods). The data of this table came from two independent microarray experiments, the first one performed on RNAs from samples A 
to D treated at the same moment, and the second from samples H to J. For this reason, we compared P1-8 with B-1 and P1-32 with B-57 
 
Table 3    Identification of 12 genes consistently and significantly repressed by PLAG1 
AB  C D E F G H I J K L M N O 
B1+ P8- P8+ P8+9h P8-/P8+9h P8-/+ B1+/P8+ B57+ P32- P32+ P32-/+ B57+/P32+ Accession Genes BS 
Growth factors            
287 279 50 279 1.0 5.6 5.7 155 157 50 3.1 3.1 Y07867 Pirin 0 
Proteins involved in metabolism          
174 170 50 289 0.6 3.4 3.5 400 163 50 3.3 8.0 AF039652 Ribonuclease H type II 1 
752 685 248 740 0.9 2.8 3.0 606 499 130 3.8 4.7 S71018 Peptidyl-prolyl-
isomerase C 
0 
459 286 50 347 0.8 5.7 9.2 215 152 50 3.0 4.3 M33494 Triptase -beta 1 4 
Miscellaneous            
358 257 50 458 0.6 5.1 7.2 483 762 50 15.2 9.7 AJ133769 Nuclear transport 
receptor 
1 
709 429 165 518 0.8 2.6 4.3 347 344 96 3.6 3.6 X04325 Gap junction beta-1 
protein 
3 
237 327 50 310 1.1 6.5 4.7 247 406 68 6.0 3.6 U90546 Butyrophilin 0 
172 254 50 188 1.3 5.1 3.4 179 169 50 3.4 3.6 AB015332 Neighbor of A-kinase 
anchoring protein 95 
1 
Unknown            
317 377 56 488 0.8 6.8 5.7 485 365 50 7.3 9.7 AI133727 Habcs0217 homo 
sapiens cDNA 
0 
297 329 75 476 0.7 4.4 3.9 423 355 50 7.1 8.5 AB020674 mRNA for KIAA0867 
protein 
NA 
161 197 50 480 0.4 3.9 3.2 326 320 50 6.4 6.5 AI344681 Qp09h03.x1 homo 
sapiens cDNA 
1 
192 252 50 286 0.9 5.0 3.8 228 307 50 6.1 4.6 AL031432 Hypothetical protein 
DJ465N24.1 
NA 
The 12 genes repressed at least threefold when comparing PLAG1 versus β-galactosidase -expressing clones, both zinc-treated (columns G 
and L), and at least 2.5-fold when comparing treated versus untreated PLAG1-expressing clones (columns F and K) are listed. Columns 
include the following information : the scaled average difference values (SADVs) for the probe sets in the different conditions (columns A-
D, H-J); the accession number of the gene corresponding to the probe set (column M); the number of PLAG1-binding motifs found in the 
first 1000 bp of their putative prom oter region (column O), NA meaning that the promoter sequences were not available. SADVs of less than 
50 were arbitrarily set to a baseline value of 50 to avoid unrealistic levels of repression (see Material and methods). The data of this table 
came from two independent microarray experiments, the first one performed on RNAs from samples A to D treated at the same moment, and 
the second from samples H to J. For this reason, we compared P1-8 with B-1 and P1-32 with B-57 
 
Identification of candidate PLAG1 target genes in pleomorphic adenomas 
The comparison of the two sets of expression profiles (tumors versus normal salivary glands and PLAG1-
expressing cells versus control cells) allowed us to identify candidate PLAG1 targets in pleomorphic adenomas 
(Figure 1). A total of 12 genes were found to be stimulated in PLAG1-expressing cells as well as in the tumors 
(genes in green in Table 2). These genes are coding for the IGF-II, the CLF-1, the bone-derived growth factor 1 
(BPGF-1), the CRABP-II, the SWI/ SNF complex 60 kDa subunit, the apoptosis regulator Bcl-2, the cyclin-
dependent kinase inhibitor 1C (p57KIP2), ephrin B-1, the neuronal pentraxin receptor, the collagen alpha 3 (IX) 
chain, the muscle isoform of filamin and the tetraspan (NAG-2). In contrast, none of the 12 downregulated genes 
have their expression significantly altered in the pleomorphic adenoma of the salivary glands. 
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Validation of the oligonucleotide microarray results 
In order to confirm the microarray analyses, we performed Northern blot analyses using six putative target genes 
as probes, that is, IGF-II, CRABP-II, CRP2, p57KIP2, CLF-1 and PIGF. As shown in Figure 2, expression levels 
of the six transcripts are extremely low or undetectable in zinc-treated β-gal-expressing clones (B-1+ and B-57+ 
; lanes 5, 6, 7, 21 and 24). The transcript levels increase slightly in untreated PLAG1-expressing clones (P1-8— 
and P1-32—; lanes 1, 3, 22, 25 and 27). This increase might be due to a leaky expression of PLAG1 in this 
system, which can be visualized after a longer exposition of the blots (data not shown). A strong induction in the 
expression of all the six transcripts is solely seen when PLAG1 expression is induced (lanes 2, 4, 23, 26 and 29), 
as predicted by the microarray results. High induction of the six targets is also obtained after 9 h of zinc 
treatment, which reaches approximately half of the stimulation observed at 16 h (lanes 8, 9 and 28). Assessment 
of the transcript levels in the tumors also correlated with the microarray data as the transcripts for PLAG1, 
CRABP-II, IGF-II and CLF-1 are solely detected in pleomorphic adenoma, while no expression is observed in 
normal salivary glands. The p57kip2 transcript is also overexpressed in the tumors compared to normal salivary 
glands, but to a lesser extent (about 2.1-fold stimulation). As for CRP2, its transcript is on average overexpressed 
3.2-fold in tumors compared to normal salivary glands, which is roughly similar to the 2.2-fold stimulation 
obtained by the microarray analysis. Finally, the PIGF transcript was not detectable, either in tumors or in 
normal salivary glands, which is in agreement with the microarray values close to the background. 
 
Figure 2 Validation of the oligonucleotides microarray results by Northern blot analyses. Northern blot analysis of total RNA isolated 
from genetically engineered human epithelial kidney 293 cell lines that have stably integrated a DNA fragment enabling zinc-inducible 
expression of PLAG1 (clones P1-8 and P1-32) or of β-gal (clones B-1 and B-57) grown without (-) or with (+) 100 µM ZnCl2 for the 
indicated times (lanes 1-9, 21-29). Also depicted are Northern blot analyses of total RNAs isolated from pleomorphic adenomas of the 
salivary glands (PA) corresponding to biopsies F32 (lane 16), F36 (lane 17), F35 (lane 18), G30 (lane 19), G18 (lanes 20 and 32) and from 
biopsies K5773, K3149 and K3259 pooled together (lane 31). The total RNA from normal salivary gland (nsg) H3 (lane 10), H1 (lane 30) 
and H2 (lanes 11-15 corresponding to different RNA preparations obtained from different part of the biopsy H2) was used for comparison. 
Blots were hybridized sequentially with different 
32
P-labeled human probes, as indicated on the left side of the figure. The sizes of the 
transcripts detected are the following: 7.5 kb for PLAG1; 6.0 kb for IGF-II corresponding to the P3 transcript; 1.2 kb for CRABP-II; 1.4kb for 
CRP2; 1.7 and 1.4kb for p57kip2 in the PLAG1-expressing cell lines, while only the 1.7 transcript is detected in the tumors; 1.7 and 1.4 kb for 
CLF-1 in the 293 cell lines, while only the 1.4 transcript is detected in the tumors and, finally, 1.7 kb for PIGF. Methylene blue-stained 
rRNA levels demonstrate similar loading and RNA quality in each lane 
 
 
Search for PLAG1 motifs in the PLAG1 target genes 
To get a clue whether the 47 upregulated genes found in this study could be direct targets of PLAG1, we 
exploited the fact that PLAG1 is a sequence-specific DNA-binding protein that interacts with the motif 
GRGGC(N)6-8GGG. Therefore, we scanned the promoter regions of these genes for the presence of this binding 
motif, banning any mismatches. As the promoter region of most of these genes was not yet defined, we 
attempted to obtain them by retrieving from the human genome database the sequences located directly upstream 
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of the cDNAs with the 5' end starting at the most upstream part of the genes (see Material and methods). 
However, it remains possible that some sequences do not correspond to the real promoter, which could be 
located upstream of an unidentified exon. As shown in Table 2 (column O), the 47 upregulated genes often 
harbor several PLAG1-binding sites in the first 1000 bp of their putative promoter regions, with an average of 
2.4 binding sites per upregulated gene. As demonstrated by the χ2 test, this value is significantly higher than the 
mean obtained for a random population of 50 promoters (1.1 binding site per gene). The distribution of the 
motifs is also clearly different in the upregulated genes compared to the random population, as illustrated in 
Figure 3. For example, 50% of the control promoters do not display any PLAG1-binding sites, while this 
percentage drops to 10% for the upregulated genes. On the contrary, 40% of the upregulated genes contain at 
least three PLAG1 motifs in comparison to 8% in the random population of promoters. 
The downregulated genes were also scanned for the presence of the PLAG1 motifs. In all, 11 consensus 
sequences were found in the 10 promoter sequences available, defining a frequency of 1.1 consensus per gene, 
which is identical to the one obtained for the random population of 50 promoters. 
 
Figure 3 Histograms illustrating the abundance of PLAG1 motifs in the promoter regions of the upregulated genes. Histogram depicting 
the percentage of genes containing zero to eight PLAG1 consensus sequences (GRGGC(N)6-8GGG) in their promoter for each population 
(the 47 upregulated PLAG1 targets and the random pool of 50 control promoters) . The χ2 test demonstrates a > 99.75% chance that there is a 




PLAG1 is a proto-oncogene recently discovered, whose ectopic expression can trigger the development of 
pleomorphic adenomas of the salivary glands (Kas et al., 1997) and of lipoblastomas (Hibbard et al., 2000). 
As PLAG1 is a transcription factor, its ectopic expression presumably leads to the deregulation of target genes. 
Their identification is therefore essential for the understanding of PLAG1-induced tumorigenesis. To date, only 
one PLAG1 target has been identified, the IGF-II gene (Voz et al., 2000). Several lines of evidence indicate that 
IGF-II is a direct target of PLAG1. First, PLAG1 is able to bind to the promoter 3 of IGF-II, which contains 
eight consensus-binding sites, and activates its promoter activity efficiently. Secondly, IGF-II transcripts 
deriving from the P3 promoter are highly expressed in salivary gland adenomas over-expressing PLAG1. In 
contrast, they are undetectable in adenomas without abnormal PLAG1 expression and in the normal salivary 
gland tissue. Finally, a drastic upregulation of the IGF-II transcript originating from the P3 promoter is observed 
shortly after inducing PLAG1 expression in the fetal kidney cell line 293 (Hensen et al., 2002). 
In order to identify other PLAG1 targets, we analysed the expression profiles of about 12000 genes after 
conditional induction of PLAG1 expression in 293 cell lines. Such cell lines have stably integrated a DNA 
fragment enabling zinc-inducible expression of PLAG1 or of β-gal (Hensen et al., 2002). In the absence of zinc, 
they expressed low levels of PLAG1 and β-gal proteins, while a strong overexpression is observed upon 
treatment with zinc chloride. PLAG1 induction leads to a strong induction of the IGF-II transcript which can 
already be visualized after about 5 h, but which peaks at 16 h. This quite tardy peak is presumably due to the fact 
that in this system, the level of PLAG1 protein reaches a plateau at 4h and remains equal for at least 12 h (data 
not shown). For most of the microarray analyses, we therefore extracted RNA after 16 h of induction, reasoning 
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that, at that time, we should have maximal induction for PLAG1 targets, with a still large proportion of direct 
targets. This choice was reinforced by the microarray analyses performed on fibroblasts constitutively expressing 
a MYC-ER protein (Coller et al., 2000). In the presence of tamoxifen, the MYC-ER protein, sequestered in the 
cytoplasm, is transported into the nucleus, where it can activate the transcription of Myc target genes. In this 
system, where the MYC-ER protein does not have to be produced, most of the MYC targets detected after 9 h of 
tamoxifen treatment were still direct targets. 
Expression profile analyses allowed us to identify 47 genes that are consistently induced upon zinc treatment of 
PLAG1-expressing clones, and also overexpressed in zinc-treated PLAG1 clones compared to the treated β-gal-
expressing clones. As illustrated in Figure 1, both comparisons were essential to identify only genuine PLAG1 
targets. Indeed, the comparison between treated versus untreated PLAG1-expressing clones highlighted, on top 
of the 47 PLAG1 target genes, 38 genes, some of which are presumably induced by the zinc treatment alone. 
Surprisingly, comparisons between PLAG1 versus β-gal-expressing clones, both zinc treated, reveal 64 genes 
not obtained by the comparisons of treated versus untreated PLAG1 clones. These genes could be differentially 
expressed due to clone disparities and/or because, even in the absence of zinc, PLAG1-expressing clones 
proliferate more rapidly than the β-gal-expressing clones. It is possible that the faint leaky PLAG1 expression 
obtained in the absence of zinc is sufficient to slightly stimulate cell proliferation, resulting in changes of 
expression of some growth-related genes. 
The search for PLAG1-binding sites in these 47 upregulated genes indicated that they contain significantly more 
binding sites than a random population of promoters (Figure 3). This is a strong indication that at least some of 
them are direct PLAG1 targets. This hypothesis is reinforced by the fact that expression profiles and Northern 
blot analysis indicate that a majority of them (30 out of 47) are already highly stimulated after 9 h of zinc 
induction. Contrary to the upregulated genes, the 12 downregulated genes do not appear to be direct PLAG1 
targets. Indeed, the promoter of these genes does not contain significantly more PLAG1 motifs compared to the 
random promoter population; secondly, none of them are already repressed after 9h of zinc induction. Based on 
this study, it thus appears that PLAG1 acts essentially as an activator of transcription. This is in accordance with 
the data showing that the C-terminal part of PLAG1 acts as a transactivation domain when fused to the GAL4 
DNA-binding domain (Kas et al., 1998). 
Interestingly, one of the largest classes identified as upregulated PLAG1 targets consists of growth factors such 
as IGF-II, the CLF-1 and the BPGF-1. These three cytokines are also upregulated in pleomorphic adenomas of 
the salivary glands displaying PLAG1 over-expression, suggesting that they are PLAG1 targets in the tumors. 
We can thus postulate that one of the roles of PLAG1 in tumor formation is to influence cell proliferation via 
induction of growth factors. The role of IGF-II as a potent stimulator of cell proliferation during embryonic 
development and tumorigenesis is well established (DeChiara et al., 1990; Baker et al., 1993; Toretsky and 
Helman, 1996; Burns and Hassan, 2001), and it is likely that at least part of the PLAG1 oncogenic potential 
passes through the induction of IGF-II expression. This is supported by our transformation studies, where we 
showed that PLAG1 is able to induce the neoplastic transformation of NIH3T3 but not of R-cells, which are 
devoid of the IGFI-R receptor, the main mediator of IGF-II effect (Sell et al., 1994; Hensen et al., 2002). The 
role of the CLF-1 on cell proliferation is not yet documented. This recently discovered growth factor associates 
with the cardiotrophin-like cytokine (CLC) to form a heterodimeric cytokine that binds and activates the   
trimeric complex constituted of the CNTFR receptor, the leukemia-inhibitory factor receptor and gpl30 (Elson et 
al., 1998, 2000). Although the signaling cascade resulting from the binding to the receptor is already well 
defmed (Lelievre et al., 2001), the role of the CLF-1 factor in terms of cellular responses has not yet been 
investigated. Until now, the only information available comes from the CLF-1-/- mice that have reduced numbers 
of hemopoietic progenitor cells, fail to suckle and die within 24 h after birth (Alexander et al., 1999). Whole 
mount in situ hybridization reveals CLF-1 expression at several sites in the developing embryo and notably in 
the secretory buds and ducts of the submandibular salivary glands at 14.5 and 18.5 dpc (Alexander et al., 1999). 
This brings the hypothesis that PLAG1 could be one of the regulators of CLF-1 expression in the developing 
salivary gland, controlling the salivary gland organogenesis via this cytokine. As for the BPGF-1, also called 
quiescin Q6, this gene is specifically expressed when cultured human lung fibroblasts begin to leave the 
proliferative cycle and enter quiescence (Coppock et al., 1993). BPGF-1 thus seems to be associated with growth 
inhibition, which presumably interferes with tumor formation. The significance of BPGF-1 overexpression in 
pleomorphic adenomas and also in some malignant breast cell lines (Coppock et al., 2000) is therefore not yet 
understood. However, Coppock et al. propose that one potential function of quiescins might be to ensure 
viability under stressful conditions that might otherwise lead to apoptosis. On the other hand, it appears from our 
microarray data that PLAG1 induces not only target genes able to promote tumor formation, but also genes that 
in contrary seem to interfere with it. The most striking example is the induction by PLAG1 of the putative tumor 
suppressor p57kip2. This factor is indeed a tight-binding inhibitor of several G1 cyclin/Cdk complexes, resulting 
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in a negative regulation of cell proliferation (Lee et al., 1995; Matsuoka et al., 1995). Diminished expression of 
p57kip2 has been found in a variety of tumors (Oya and Schulz, 2000; Schwienbacher et al., 2000; Ito et al., 
2002a) and, to our knowledge, pleomorphic adenoma is one of the few cases with hepatoblastomas (Hartmann et 
al., 2000) and thyroid neoplasms (Ito et al., 2002b) of a p57kip2 overexpression. Another example of PLAG1-
induced genes with growth-inhibitory potential is the gene coding for the CRABP-II. CRABP-II potentiates the 
transcriptional activity of the retinoic acid receptor via its ability to channel retinoic acid to the receptor (Budhu 
and Noy, 2002). Overexpression of CRABP-II in MCF-7 mammary carcinoma cells dramatically enhances their 
sensitivity to retinoic acid-induced growth inhibition. Conversely, diminished expression of CRABP-II renders 
MCF-7 and squamous cell carcinoma SCC25 much less sensitive to retinoic acid-mediated inhibition of 
proliferation (Vo and Crowe, 1998; Budhu and Noy, 2002). These seemingly contradictory actions of PLAG1 
targets on tumor formation could be one of the reasons as to why PLAG1 triggers only the formation of benign 
tumors such as pleomorphic adenomas of the salivary glands and lipoblastomas. We could hypothesize that the 
balance between PLAG1 targets promoting and inhibiting tumor formation is in favor of a weak induction of cell 
proliferation as observed in pleomorphic adenoma (Zhu et al., 1997; Frade Gonzalez et al., 2001). The low rate 
of proliferation, scarcely propitious to accumulate additional mutations necessary for the tumor to become 
malignant, could explain the fact that pleomorphic adenomas of the salivary glands rarely give rise to a 
malignant tumor. 
Our expression profile analyses also reveal that PLAG1 could be involved in a variety of cellular processes, and 
notably in vasculogenesis and/or angio-genesis. Indeed, the identification as upregulated PLAG1 targets of the 
vascular endothelial growth factor (VEGF) and the placental growth factor (PIGF), both known as potent 
mitogen for endothelial cells (Conway et al., 2001), is highly suggestive of a role of PLAG1 in controlling blood 
vessel formation. This hypothesis is reinforced by the upregulation by PLAG1 of Ephrin B1, which is involved 
in the sprouting of new vessels (Conway et al., 2001). Such hypothesis will be verified in mice with a targeted 
disruption of the PLAG1 gene, as well as in transgenic mice with conditional induction of PLAG1 expression. In 
the same way, the biological significance of the other PLAG1 targets will be evaluated in these mouse models. 
The identification of a number of PLAG1 targets in this study, besides giving us insights into understanding how 
PLAG1 activation contributes to salivary gland tumorigenesis, will also be a valuable and indispensable tool for 
the molecular comprehension of PLAG1 function during embryogenesis. 
Abbreviations 
PLAG1, pleomorphic adenoma gene 1; IGF-II, insulin-like growth factor II; PA, pleomorphic adenoma of the 
salivary glands; nsg, normal salivary gland; p57kip2, cyclin-dependent kinase inhibitor 1C; CRABP-II, cellular 
retinoic acid-binding protein II; CLF-1, cytokine-like factor 1; CRP2, cysteine-rich protein 2; PIGF, placental 
growth factor; SADV, scaled average difference value. 
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